inVentiv Health has extended its partnership with NeuroVive Pharmaceutical AB to bring their drugs to treat acute cardiovascular and neurological conditions to market.
Mark Archer, SVP of commercial operations and development, told Outsourcing-Pharma.com that the deal fits with the CRO’s strategy at the moment to focus on mid-size biotech companies.
“We’re still in discussions on the details of the clinical trials but this is more complete than most of the deals we do,” Archer said.
inVentiv offers a set of services that run from early-stage clinical development to full global commercialization.
NeuroVive’s portfolio of mitochondrial drugs in development will aim to treat acute cardiovascular and neurological conditions.
They are currently in the planning stage for commercialization of their lead product, CicloMulsion, which is now in a Phase III study to determine the drug’s effectiveness in reducing cardiac damage following stenting in heart attack patients.
NeuroVive is looking for a partner with an alternative business model that can commercialize CicloMulsion and be leveraged to scale for future products.
“We’re also sharing some risk in this partnership,” Archer continued. “We’re looking at global development and registration so it’s different from a typical deal we would make with a pharmaceutical company.”
NeuroVive already is accessing inVentiv services and recently completed a one-year regulatory consulting project with ParagonRx, inVentiv’s risk mitigation service. inVentiv will next be providing market assessment services through its consulting arm, Campbell Alliance.
“We’re big enough to step in and provide NeuroVive with virtually any service they require to develop and commercialize their compound, and we’re flexible enough to align with whatever they need to achieve their objectives,” said Dan Feldman, President of inVentiv Health Europe.
”We are very pleased to extend the collaboration with inVentiv Health, an important step in preparing the market for launch of CicloMulsion in Europe and, later, in the United States,” said Mikael Brönnegård, CEO of NeuroVive Pharmaceutical AB.